Últimas noticias sobre Marsh & McLennan Cos (NYSE:MMC) Bolsa

MARSH & MCLENNAN COS

Marsh & McLennan

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

Movimiento de acciones

AEHL

AMBC

BTOG

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.78% on an annualized basis producing an average annual return of 14.26%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $106.91 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 10 years ago, it would be worth $3,791.86 today based on a price of $216.97 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751063412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Marsh & McLennan Cos Stock In The Last 10 Years

Marsh McLennan's Oliver Wyman To Acquire Validate Health; No Terms Disclosed

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 15.96%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $105.60 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 15 years ago, it would be worth $935.49 today based on a price of $214.32 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750343415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan Cos 15 Years Ago Would Be Worth Today

WIIM

Shares of auto-insurance companies are trading lower after a Goldman Sachs note indicated that insurance costs are projected to decline due to disruptions from self-driving cars, which may result in fewer accidents and shifting risks.

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 3.97% on an annualized basis producing an average annual return of 14.8%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $114.08 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 10 years ago, it would be worth $3,980.91 today based on a price of $231.53 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748384110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 10 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $229.22, after a 0.33% increase. Over the past month, Marsh &amp; McLennan Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) stock increased by 4.55%, and in the past year, by 12.38%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748012423_0.png" alt="Past Year Chart" />

<h3>Comparing Marsh &amp; McLennan Cos P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 56.57 in the Insurance industry, Marsh &amp; McLennan Cos Inc. has a lower P/E ratio of 28.03. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748012423_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Marsh & McLennan Cos

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.64% on an annualized basis producing an average annual return of 14.78%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.92 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,844.79 today based on a price of $227.13 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746631889_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth Today

Marsh &amp; McLennan Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has risen 13.33% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 1.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746453626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan Cos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Marsh &amp; McLennan Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Marsh &amp; McLennan Cos's peer group average for short interest as a percentage of float is 2.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Marsh & McLennan Cos's Recent Short Interest

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Underperform and lowers the price target from $220 to $215.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Underperform on Marsh & McLennan Cos, Lowers Price Target to $215

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.83% on an annualized basis producing an average annual return of 14.73%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $108.47 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 20 years ago, it would be worth $1,560.78 today based on a price of $220.07 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745019912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive <a href="https://www.benzinga.com/topic/donald-trump">momentum in trade negotiations.</a>
Speaking ahead of a scheduled meeting with Italian Prime Minister Giorgia Meloni, Trump expressed strong confidence in reaching a trade agreement with the European Union. He also hinted at progress with China, stating, "We will make a good deal with China." 
Meanwhile, U.S. Treasury Secretary Scott Bessent noted that trade talks with Japan are moving in a highly satisfactory direction.
By midday in New York, the S&amp;P 500 had climbed 0.9%, while the Nasdaq 100 gained 0.5%, recouping some losses after a 3% slide on Wednesday. The Dow Jones, however, slipped 0.9%, weighed down by a sharp 23% plunge in UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) after the company slashed its full-year earnings forecast.
Energy stocks led the day&#8217;s gains, buoyed by rising oil prices. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) rallied 4.1%, while Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) advanced 3.5%.
Gold prices retreated nearly 1% after a strong multi-day rally, pressured by a firmer U.S. dollar and rising Treasury yields. The 10-year Treasury yield climbed six basis points to 4.34%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.9% to $85,000.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,884.35</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,323.43</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,357.77</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,441.72</td>
<td colspan="2">-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $530.09.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $394.05.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $446.19.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1% to $186.67.</li>
<li>The&nbsp;Energt&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 3.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Eli Lilly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) surged 16% after announcing that its oral GLP-1 receptor agonist, Orforglipron, successfully completed Phase 3 trials without requiring food or water restrictions.</li>
<li>Fidelity National Information Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) jumped 9% after announcing a $13.5 billion deal to acquire Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)&#8217;s Issuer Solutions business. The move is aimed at bolstering FIS's fintech capabilities and is expected to generate over $125 million in annual revenue synergies. Shares of GPN tumbled 15%. </li>
<li>Companies reacting to earnings reports included American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), up 0.5%; Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), up 1.9%; Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), up 2.7%; Marsh &amp; McLennan Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) down 3.3%; Truist Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), up 1.3%; State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>), up 3.2%; KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), up 3.7% and Huntington Bancshares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>), up 4%.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose 2% ahead of the earnings report, which is slated for release after the market close. </li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

HBAN

NFLX

SCHW

Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?

Marsh & McLennan shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) reported quarterly earnings of $3.06 per share which beat the analyst consensus estimate of $3.02 by 1.32 percent. This is a 4.79 percent increase over earnings of $2.92 per share from the same period last year. The company reported quarterly sales of $7.06 billion which missed the analyst consensus estimate of $7.08 billion by 0.31 percent. This is a 9.08 percent increase over sales of $6.47 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Marsh & McLennan Q1 Adj EPS $3.06 Beats $3.02 Estimate, Sales $7.06B Miss $7.08B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $250.69 million. 
• Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $23.92 billion. 
• Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $220.76 million. 
• Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $5.54 billion. 
• Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $1.97 billion. 
• ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $3.96 billion. 
• State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) is likely to report quarterly earnings at $2.01 per share on revenue of $3.32 billion. 
• American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is expected to report quarterly earnings at $3.47 per share on revenue of $16.93 billion. 
• Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) is estimated to report quarterly earnings at $3.00 per share on revenue of $7.08 billion. 
• D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.03 billion. 
• Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) is projected to report quarterly earnings at $4.82 per share on revenue of $1.21 billion. 
• Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $363.15 million. 
• Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $2.16 billion. 
• Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) is estimated to report quarterly earnings at $0.95 per share on revenue of $283.30 million. 
• Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.83 billion. 
• Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.68 billion. 
• Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $4.94 billion. 
• UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is likely to report quarterly earnings at $7.29 per share on revenue of $111.60 billion. 
• Insteel Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $149.85 million. 
• Hooker Furnishings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFT#NASDAQ">HOFT</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $101.16 million. 
• Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $1.89 billion. 
• Infosys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $4.90 billion. 
• KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $1.75 billion. 
<h3>Companies Reporting After The Bell</h3>
• Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is expected to report quarterly earnings at $5.72 per share on revenue of $10.51 billion. 
• Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) is expected to report quarterly earnings at $1.16 per share on revenue of $175.04 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

FITB

HOFT

IIIN

INDB

INFY

TCBI

Earnings Scheduled For April 17, 2025

In the current session, the stock is trading at $233.91, after a 0.67% increase. Over the past month, Marsh &amp; McLennan Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) stock increased by 1.03%, and in the past year, by 16.47%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1744819229_0.png" alt="Past Year Chart" />

<h3>Evaluating Marsh &amp; McLennan Cos P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 62.22 in the Insurance industry, Marsh &amp; McLennan Cos Inc. has a lower P/E ratio of 28.41. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744819229_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-17. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Marsh &amp; McLennan to report an earnings per share (EPS) of $3.09.
The announcement from Marsh &amp; McLennan is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.11, leading to a 1.79% drop in the share price the following trading session.
Here's a look at Marsh &amp; McLennan's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.76</td>
<td>1.61</td>
<td>2.40</td>
<td>2.80</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.87</td>
<td>1.63</td>
<td>2.41</td>
<td>2.89</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744812084_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Marsh &amp; McLennan were trading at $232.36 as of April 15. Over the last 52-week period, shares are up 15.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Marsh &amp; McLennan</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Marsh &amp; McLennan.
With 8 analyst ratings, Marsh &amp; McLennan has a consensus rating of Neutral. The average one-year price target is $236.12, indicating a potential 1.62% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Arthur J. Gallagher, Aon and Brown &amp; Brown, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Arthur J. Gallagher, with an average 1-year price target of $324.1, suggesting a potential 39.48% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Aon, with an average 1-year price target of $414.0, suggesting a potential 78.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Brown &amp; Brown, with an average 1-year price target of $120.0, suggesting a potential 48.36% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Arthur J. Gallagher, Aon and Brown &amp; Brown are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marsh &amp; McLennan Cos</td>
<td>Neutral</td>
<td>9.24%</td>
<td>$2.44B</td>
<td>5.83%</td>
</tr>
<tr>
<td>Arthur J. Gallagher</td>
<td>Neutral</td>
<td>11.68%</td>
<td>$1.13B</td>
<td>1.60%</td>
</tr>
<tr>
<td>Aon</td>
<td>Outperform</td>
<td>22.87%</td>
<td>$2.03B</td>
<td>11.58%</td>
</tr>
<tr>
<td>Brown &amp; Brown</td>
<td>Neutral</td>
<td>12.04%</td>
<td>$506M</td>
<td>3.21%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Marsh &amp; McLennan ranks in the middle among its peers for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, while it is at the top for Return on Equity.
<h3>About Marsh &amp; McLennan</h3>
Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.
<h3>Marsh &amp; McLennan's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Marsh &amp; McLennan showcased positive performance, achieving a revenue growth rate of 9.24% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Marsh &amp; McLennan's net margin excels beyond industry benchmarks, reaching 12.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Marsh &amp; McLennan's ROE excels beyond industry benchmarks, reaching 5.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Marsh &amp; McLennan's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.48% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Marsh &amp; McLennan's debt-to-equity ratio is below the industry average at 1.64, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MMC/earnings">To track all earnings releases for Marsh &amp; McLennan visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Marsh & McLennan's Quarterly Earnings

Marsh &amp; McLennan Cos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) short percent of float has fallen 27.42% since its last report. The company recently reported that it has 4.43 million shares sold short, which is 0.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Marsh &amp; McLennan Cos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744729230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marsh &amp; McLennan Cos has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Marsh &amp; McLennan Cos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Marsh &amp; McLennan Cos's peer group average for short interest as a percentage of float is 2.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Marsh & McLennan Cos?

Barclays analyst Alex Scott maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $246 to $249.

Barclays Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $249

Jefferies analyst Yaron Kinar maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Hold and raises the price target from $237 to $244.

Jefferies Maintains Hold on Marsh & McLennan Cos, Raises Price Target to $244

Press Releases

Marsh McLennan Agency Acquires Arthur Hall Insurance

Marsh McLennan Reports First Quarter 2025 Results

Marsh McLennan's Mercer Completes Acquisition of SECOR Asset Management

Employers face rising healthcare costs from climate risks and new forecasting tool helps them assess the impact

Insurance

GI Partners Teams with Industry Veterans Brad Emmons and Brian Hanuschak to Launch Tech-Enabled MGA Platform

Oliver Wyman Unveils Comprehensive Labor Cost Per Vehicle Analysis Amidst Changing Automotive Landscape

Marsh McLennan Stockholders Re-Elect Board of Directors During 2025 Meeting

Marsh McLennan to Host Second Quarter Earnings Investor Call on July 17

Marsh McLennan's Oliver Wyman to Acquire Healthcare Analytics Business Validate Health

Comments

Marsh & McLennan Cos

Noticias

Últimas noticias sobre Marsh & McLennan Cos (NYSE:MMC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL